Leclerc Estelle, Vetter Stefan W
Department of Pharmaceutical Sciences, North Dakota State University, PO Box 6050, Department 2665, Fargo, ND 58108-6050, USA.
Department of Pharmaceutical Sciences, North Dakota State University, PO Box 6050, Department 2665, Fargo, ND 58108-6050, USA.
Biochim Biophys Acta. 2015 Dec;1852(12):2706-11. doi: 10.1016/j.bbadis.2015.09.022. Epub 2015 Oct 3.
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with low survival rates. Current therapeutic treatments have very poor response rates due to the high inherent chemoresistance of the pancreatic-cancer cells. Recent studies have suggested that the receptor for advanced glycation end products (RAGE) and its S100 protein ligands play important roles in the progression of PDAC. We will discuss the potential role of S100 proteins and their receptor, RAGE, in the development and progression of pancreatic cancer.
胰腺导管腺癌(PDAC)是一种生存率很低的毁灭性疾病。由于胰腺癌细胞固有的高化学抗性,目前的治疗方法反应率非常低。最近的研究表明,晚期糖基化终产物受体(RAGE)及其S100蛋白配体在PDAC的进展中起重要作用。我们将讨论S100蛋白及其受体RAGE在胰腺癌发生和发展中的潜在作用。